“The tumor uptake rate was to 80-100%, which is a huge advantage because what we could achieve as a statistical significance with 8-12 mice, can be achieved with 5-6 OncoRats.” — Ramesh Narayanan, Ph.D., Associate Professor of Medicine & Hematology at the University of Tennessee Health Science Center.
“(The) Cas-CLOVER hybrid gene editing system fuses a functionally inactive Cas9 to the site-specific nuclease, Clo51. Cas-CLOVER is targeted using a set of two distinct gRNAs, operating like CRISPR-Cas9, but (the) system has the exquisite specificity of type IIS nucleases and causes no or very few off-target mutations. We can use this high-fidelity system to safely develop off-the-shelf CAR T-cell products.” Devon J. Shedlock, Ph.D., vice president, preclinical development, Poseida Therapeutics. GEN Article True CRISPR: A Genetic Genre with Novel Twists